SMARCB1 and follicular lymphoma: Tazemetostat (EPZ6438) is a SAM-competitive EZH2 inhibitor that has been approved by the FDA for the treatment of epithelial sarcoma characterised by loss of integrase interactor 1/SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (INI1/SMARCB1) and follicular lymphoma (FDA, 2020a; FDA, 2020b).